The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy
oleh: Rodrigo Santacruz, Neus Villamor, Marta Aymerich, Alejandra Martínez-Trillos, Cristina López, Alba Navarro, María Rozman, Sílvia Beà, Cristina Royo, Maite Cazorla, Dolors Colomer, Eva Giné, Magda Pinyol, Xose S. Puente, Carlos López-Otín, Elías Campo, Armando López-Guillermo, Julio Delgado
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2014-05-01 |
Deskripsi
A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2–202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (P